Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML (NCT06533761)

🔬

Loading study...

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML (NCT06533761) | TrialReferrals